Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups

Patients with metastatic renal cell carcinoma (mRCC) have better overall survival when treated with nivolumab, a cancer immunotherapy that targets the immune checkpoint inhibitor programmed cell death 1 (PD-1), rather than everolimus (a chemical inhibitor of mTOR and immunosuppressant). Poor-risk mR...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Immunol Res
Auteurs principaux: de Velasco, Guillermo, Miao, Diana, Voss, Martin H., Hakimi, A. Ari, Hsieh, James J., Tannir, Nizar M., Tamboli, Pheroze, Appleman, Leonard J., Rathmell, W. Kimryn, Van Allen, Eliezer M., Choueiri, Toni K.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050137/
https://ncbi.nlm.nih.gov/pubmed/27538576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0110
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires